CareDx ( (CDNA) ) has provided an announcement.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
CareDx, Inc., a leader in precision medicine for transplant patients, has announced its preliminary financial results for Q3 2024, highlighting a strong performance with an expected revenue increase of 23% year-over-year, reaching $82-$83 million. The company saw significant growth in testing services and patient solutions, resulting in a remarkable 16% rise in testing volume. With cash reserves of approximately $240 million and no debt, CareDx is well-positioned for future growth, as it prepares for the official earnings release on November 4, 2024.
For an in-depth examination of CDNA stock, go to TipRanks’ Stock Analysis page.